Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at BidaskClub

Akebia Therapeutics (NASDAQ:AKBA) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, BidAskClub reports.

AKBA has been the topic of a number of other research reports. ValuEngine upgraded shares of China Southern Airlines from a “sell” rating to a “hold” rating in a report on Tuesday, June 11th. Citigroup started coverage on shares of Akebia Therapeutics in a report on Wednesday, March 20th. They issued a “neutral” rating and a $9.00 price objective on the stock. Finally, JPMorgan Chase & Co. set a €28.20 ($32.79) price objective on shares of AXA and gave the stock a “buy” rating in a report on Thursday, May 2nd. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $13.92.

Shares of NASDAQ:AKBA traded down $0.06 during midday trading on Tuesday, hitting $4.22. 696,150 shares of the company’s stock traded hands, compared to its average volume of 1,171,486. The company has a current ratio of 1.71, a quick ratio of 1.15 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $490.30 million, a P/E ratio of -1.73 and a beta of 1.49. The firm has a fifty day moving average price of $4.52. Akebia Therapeutics has a twelve month low of $4.08 and a twelve month high of $10.73.



Akebia Therapeutics (NASDAQ:AKBA) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.02). The business had revenue of $72.67 million for the quarter, compared to analyst estimates of $83.69 million. Akebia Therapeutics had a negative net margin of 82.14% and a negative return on equity of 45.06%. On average, equities research analysts forecast that Akebia Therapeutics will post -1.39 EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. First Quadrant L P CA acquired a new stake in shares of Akebia Therapeutics in the 1st quarter valued at about $43,000. Great West Life Assurance Co. Can raised its stake in shares of Akebia Therapeutics by 80.1% in the 4th quarter. Great West Life Assurance Co. Can now owns 8,418 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 3,743 shares in the last quarter. Advisor Group Inc. raised its stake in shares of Akebia Therapeutics by 3,206.3% in the 4th quarter. Advisor Group Inc. now owns 9,919 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 9,619 shares in the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Akebia Therapeutics in the 4th quarter valued at about $57,000. Finally, Jane Street Group LLC acquired a new stake in shares of Akebia Therapeutics in the 4th quarter valued at about $57,000. Hedge funds and other institutional investors own 70.50% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.

Further Reading: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.